Collaborative, Licensing and Other Arrangements - Servier - Additional Information (Details) - Collaborative Arrangement [Member] - Servier [Member] - USD ($) |
3 Months Ended | 6 Months Ended | 9 Months Ended | ||
|---|---|---|---|---|---|
Sep. 30, 2017 |
Sep. 30, 2016 |
Mar. 25, 2016 |
Sep. 30, 2017 |
Sep. 30, 2016 |
|
| Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] | |||||
| Future initial research and development expenses to be funded by counterparty | $ 50,000,000 | ||||
| Deferred revenue recognized | $ 600,000 | ||||
| Contract and other revenue | $ 0 | $ 0 | $ 0 | $ 300,000 | |
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. No definition available.
|
| X | ||||||||||
- Definition Amount of revenue recognized that was previously reported as deferred or unearned revenue. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Contract and other revenue. No definition available.
|
| X | ||||||||||
- Definition The aggregate amount of future initial clinical research and development expenses that will be funded by the counterparty. No definition available.
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|